Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elon indicated metals producers should be in your portfolio
if you're in the EV biz that would offset demand surge pricing.
Seems logical to me
Shorts continue covering
Looks to me Bankster paper pimps holding down Gold to
keep Silver from breaking out. Silver chart is still in med term uptrend while gold
keeps getting pushed down into the mud.
Someone starts a Gold and Silver backed block chain we would see the REAL
value of these metals. As long as they can print paper contracts and
move delivery tickets around a room this scam continues.
World is printing trillions yet Gold goes down? Doesn't pass the smell test.
RIOT got way ahead of its self I expect to see
R settle back into mid 50's Mara sideways low -mid 40's until installation
news, just my guess
Think 103,000 target is year end
It's a race as many others will join in but those that have facilities and
low cost power supply will be years ahead of those talking about building facilities
MARA hashrate should catch up to riot by May.
IF
Miners are delivered and installed on time with results
that of their model. If that uncertainty comes out the
gap will close.
Both are going to 100+
MARA BTC purchase of 4812 BTC is up 96 million at todays price
$25 spread between RIOT and MARA once install update
happens that gap will close IMO
Bought a slug high 3's recovery play
CC should be interesting
we shall see
71% complete Remission for bladder cancer
FDA approval eminent IMO
many more in the Pipeline
If Covid cure works this summer
SP will be ????? I have no idea!
Take a look at Jan 2022 35 calls
still cheap IMO .....going to 150
I own them and others
JMO as you know
mick take a look at
OMQS secured Homeland Security contract today
only 2 million float 4 million OS
that one going higher
in MARA board. Great NK news today. Thanks
OMQS gets contract with Homeland Security - Wow!
https://finance.yahoo.com/news/omniq-q-shield-awarded-ai-140000381.html
Thanks mick now do
MARA it's my #2 holding behind NK. Put it on your radar
Rob needs to get Elon to fund Los Azules Copper mine
and spin it out 10-1
Batteries need a lot of copper
Great NK News!
These T cells will kill the virus not mask it's receptors.
Oral Vaccine stable at room temperature being tested
3.71 (14.1%) Upgrade to Real-Time
Afterhours (Closed)
ImmunityBio & NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Ora...
February 11 2021 - 06:13PM
Business Wire
FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T cells to both Spike (S) and Nucleocapsid (N) antigens, as well as generate systemic and mucosal antibodies
The first COVID-19 trials conducted to deliver both S and N proteins via multiple routes (skin, gut, or under the tongue) to activate the entire immune system and drive T-cell and B-cell memory, which are required for long-term immune protection
Oral, room-temperature boost that stimulates immunity to both S and N proteins could potentially serve as a universal boost to other S-based vaccines while also targeting escape mutants
Testing of novel combination of oral boost to subcutaneous prime is based on positive NIH/BARDA-sponsored non-human primate data showing potent T-cell and antibody response to hAd5 after oral boost, with rapid inhibition of virus replication to undetectable levels following SARS-CoV-2 challenge
ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials of their vaccine candidate, which is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus.
The expectations of inducing protective immune responses in healthy volunteers – with this novel combination of an oral boost with a subcutaneous prime – are based on the positive findings reported in the NIH/BARDA-sponsored Non-Human Primate (NHP) study. This recent data showed that when administered with an oral boost, the bivalent vaccine resulted in potent stimulation of S- and N-specific T cells with potent antibody release from memory B cells following viral challenge. Additionally, activation of the full immune system by S and N proteins resulted in complete viral clearance of SARS-CoV-2 in lung and nasal passages following the challenge. On the basis of these findings, ImmunityBio has expanded the current Phase 1 study of subcutaneous prime with oral or sublingual boost to explore the potential of this second-generation vaccine to reduce disease and transmission of the virus.
The oral trial is a new study (NCT04732468) and the sublingual trial is the cohort C expansion to the Phase 1 subcutaneous trial (NCT04591717), which was initiated last Fall. Both oral and sublingual trials are anticipated to begin this month and will be conducted at two sites in California. Based on the findings of these trials involving over 100 participants, the optimal combination of route of administration and dose will be determined and entered into the Phase 2 / 3 design.
“The NHP study findings reinforce our hypothesis that a T-cell-based vaccine could be protective, not only in preventing mild, moderate, and severe disease, but also in potentially limiting transmission of the virus,” said Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio. “We believe that the key to creating long-term immunity to the SARS-CoV-2 virus and overcoming the variants that are rapidly developing around the world is to create a vaccine that activates not only antibodies but also memory B and T cells to multiple antigens. Furthermore, room-temperature stable formulations for oral delivery have the potential to solve the cold-chain challenges of distribution and the ability to generate mucosal IgA antibody barriers to the virus in the upper respiratory tract where it first enters the body.”
One Vaccine, Two Trials, Three Routes of Immune Protection
The first two cohorts of the Phase Ib, open label, dose-ranging study (NCT04591717) of the vaccine received two different dose levels (.5 and 1ml). Participants received two subcutaneous injections 21 days apart. No grade three or four AEs and no SAEs were observed at either dose level and, in the intermediate (1ml) dose group, immunogenicity was observed as early as 14 days after the prime. An additional group of 40 subjects will be enrolled to evaluate safety, reactogenicity, and immunogenicity of the combination of hAd5 in four different cohorts receiving sublingual and subcutaneous formulations to select an optimal combination dose for future studies.
The second Phase 1b trial (NCT04732468) is designed to assess the safety, reactogenicity, and immunogenicity of the combination of hAd5 in oral capsule and subcutaneous formulations; and to select an optimal combination dose for future studies. Up to 65 subjects will be enrolled in the four-cohort study, which is anticipated to begin in Q1.
About the T-Cell-Based Vaccine Candidate
Developed by ImmunityBio and manufactured by NantKwest, this second generation hAd5 vectored vaccine is unique in targeting both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins to generate B and T cell memory to these antigens and long-term immunity to the virus. Most of the COVID-19 vaccines approved by the FDA or in late-stage clinical trials deliver only the spike protein, which has already mutated several times. Another unique characteristic of the hAd5 design is its use of a second-generation hAd5 platform that was developed to elicit anti-SARS-CoV-2 immune responses even in Ad-immune individuals, meaning subjects can receive the vaccine multiple times, if necessary. The stimulation of anti-hAd5 immune responses is attenuated with the second-generation platform in comparison with the first-generation platforms, due to additional genetic deletions. The hAd5 room temperature-stable oral capsules were developed in partnership with UK-based biotechnology company iosBio.
Phase I trials have been initiated in the U.S. and recruitment is set to begin in February in Cape Town, South Africa for a trial (NCT04710303) of subcutaneous administration to be followed by additional trials using sublingual delivery and room temperature-stable oral capsules.
NantKwest Transaction
As previously announced, on December 21, 2020, ImmunityBio entered into an agreement to combine in a stock-for-stock transaction with NantKwest (NASDAQ: NK). The combination, which is expected to close in the first half of 2021, will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease.
About ImmunityBio
ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term “immunological memory.” This novel approach is designed to eliminate the need for high-dose chemotherapy, improve upon the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.
ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.
Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). The company is also in Phase 2 or 3 trials for indications such as first- and second-line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company’s synthetic immune modulator (Aldoxorubicin).
ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine technologies.
About NantKwest
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit www.nantkwest.com.
Forward-Looking Statements
15 million in new orders in 1 month
https://finance.yahoo.com/news/omniq-receives-2-1-million-140000727.html
It's coming IMO silver inventory
is very low and trillions going to flood the world.
It will show up in metals at some point.
Even Elon Musk talking about Gold
Bought more at .98
The manipulation does seem operational for some
time now. Doesn't make sense to short a profitable company at
19.44% sub dollar unless there is another agenda.
Gold getting crushed helps them as well.
Van Eck is a buyer. Need metals to
break higher silver back to 30 GLD break and hold 1850
Borrow rate jumped to 19.44% shorts going to get crushed
here if metals break out.
Largest borrow rate increases among liquid names (TheFlyOnTheWall)
BY The Fly
— 8:45 AM ET 02/03/2021
Latest data shows the largest indicative borrow rate increases among liquid option names include: (PSAC) 9.03% +2.65, Northern Genesis Acquisition Corp ( NGA ) 9.31% +1.41, Sempra Energy ( SRE
Loading...
Loading...
) 1.15% +0.90, Renaissance IPO (IPO) 16.42% +0.79, Churchill Capital Corp IV ( CCIV
Loading...
Loading...
) 1.30% +0.73, SPI Energy ( SPI
Loading...
Loading...
) 72.21% +0.66, Alexco Resource ( AXU
Loading...
Loading...
) 27.93% +0.48, Great Panther Silver (GPL) 19.44% +0.34, Northern Dynasty (NAK) 12.56% +0.31, and Pershing Square Tontine Holdings ( PSTH
Loading...
Loading...
) 0.90% +0.15.
Looks like shorts working desperately to get this down going
into options expiration tomorrow.
Bought the dip yesterday
17,000 bit miners on track to be operational by end of April
I Like OMQS way behind it's peers valuation and
getting traction in multiple sectors.
Partnerships with Zebra and Check Point
should start bearing fruit this year.
Been here watching it grow for a looong time.
It's time to uplist IMO
REKR hit a high of 17.49 with 10 times the float of OMQS
Hash rate will start climbing with 4,000 new bit miners and converting 150
million fiat money into BTC at 33,000 now looks kinda genius.
They have plenty of cash to burn to mine BTC at a cost of $3,800- crazy profit margins.
That little purchase put 65 million on the balance sheet.
When people start to put 2 & 2 together MARA is going to rocket provided
BTC stays above 42K and they come close to hash rate growth projections.
All JMO of course
I like MARA to 100
just my guess not financial advice
Triple top at 5 or break out
Look at MSTR chart. MARA could look similar this time next year IF
BTC goes to 300k target
MARA will mine and retain BTC growing core asset value
which will minimize exposure to mining biz long term
I like NK
BTC moves over 42k MARA goes to 40
I Like MUX
If I banked serious profits in Digital gold and
the global head hunters like India Central Bank, IMF and FED
talking about out lawing or restricting BTC I'd consider owning
some non digital assets. Silver, Gold or real estate.
Shortage in Physical nec
agreed
I like NK to 100 see FATE
Market looking a bit shaky. We shall see
MUX has high action coming
Definitely put on radar. Big volume last week.
If Copper project
in Argentina gets funded or Spun out
SP could do something stupid. Gold and silver need to break old highs.
Rob should ask Elon to fund Los Azules spin out. Batteries need a lot of copper
MUX would go to 25 my guess.
http://cdn.parabolicarc.com/wp-content/uploads/2010/10/Zero_G_Cameron_Flight.jpg
Maxine Waters's husband owned a bank that was bailed out
after 08. Ever notice the criminals sing the loudest.
"We're here for the people" it's all theater from the psychopaths
minions that run this world.
McEwen Mining: Progress Update
MUX
+0.83%
More content below
McEwen Mining
Fri, January 29, 2021, 3:45 AM
MUX
+0.83%
More content below
Operations Moving Forward, Future Growth Taking Shape, Financing Closed
TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is pleased to provide an update on its progress so far this year along with a timeline for deliverables in 2021 and recent financing activities.
Timmins, Canada
The Fox Complex has a combined resource base of 3 million oz(1) of gold and we have ambitious plans for these assets. Independent technical consultants have been employed to develop a Preliminary Economic Assessment (PEA) to expand the production from the current short mine life producing 30-40,000 oz gold per year to a ten-year mine life with annual production of 100-150,000 oz gold per year. Early results are encouraging.
The turnaround at the Black Fox Mine is progressing, with development of the underground access to the Froome deposit ahead of schedule. The first ore from Froome is planned to be delivered to the mill later this quarter and commercial production is expected to begin in Q4 of this year.
Underground drilling at the Black Fox Mine continues to return encouraging high-grade intercepts that illustrate the potential of the mine. These recent results are from delineation drilling:
64.7 g/t gold over 2.0 m core length (1.0 m TW(2)) from hole 300-F892-03 (300 level West Flank)
50.8 g/t gold over 5.6 m core length (1.3 m TW) from hole 460-L249-02 (460 level Central Zone)
37.7 g/t gold over 2.6 m core length (1.0 m TW) from hole 460-L249-06 (490 level Central Zone)
12.7 g/t gold over 3.2 m core length (2.0 m TW) from hole 490-L310-14 (490 level Central Zone)
At the Stock property, surface exploration drilling is underway with three drills on the Stock West target, and one drill testing for the extension of economic mineralization below the historic workings of the Stock Mine. Assuming this drilling is successful in identifying sufficient gold to support a decision to re-open the historic Stock Mine, we are well positioned to act quickly and begin dewatering the mine in the second half of this year. Previously the mine was dewatered in just 4 months via the existing shaft workings.
Nevada, USA
On January 7th, we updated resource and reserve numbers for our Gold Bar Mine. As a result of the 16% overall reduction in estimated reserves, an updated Feasibility Study has been completed and the report will be published by February 23rd.
Exploration drilling has resumed on targets close to the mine. On our adjoining Tonkin property, we have an oxide deposit that we are assessing as a potential source of production that may also extend the mine life of Gold Bar.
Argentina
The San José mine, which is operated by our joint venture partner Hochschild Mining, has resumed production after being temporarily closed during Q4 2020 due to government-imposed quarantine measures. The mine performed well in 2020 despite interruptions due to COVID-19 issues. We are pleased to report that we have just received our first dividend for the year from our 49% interest in the San José mine.
On January 20th, Hochschild released encouraging exploration drilling results from San José including: 1.3 m @ 13.8 g/t Au and 3,149 g/t Ag (SJD-2188, Ramal HVNX vein), and 1.6 m @ 5.6 g/t Au and 648 g/t Ag (SJD-2210, Isabel vein).
At our Los Azules copper project, we expect to provide an update on the construction of a new access road to the project in the coming months. This critical infrastructure would provide year-round access to the project, compared to the current road which is only passable 5 months of the year. The Los Azules PEA published in 2017 projected a robust operation at $3/lb copper. With the improving copper price, interest in the project has increased.
We are currently evaluating two alternatives to realize more value for our shareholders: one is pursuing a joint venture with a senior mining company to bring the project into production; and the other alternative is spinning out the asset into a new public company. Concurrently we are looking at opportunities to improve the economics of Los Azules with ore sorting technologies.
Mexico
The Fenix Feasibility study, that envisions a gold and silver mine with a 9.5-year life, will be published by February 15th. The project is turn-key with permits in hand, as well as an established local workforce.
FINANCING
We have closed the previously announced private placement offering (the “Offering”) of 12,600,600 flow-through common shares (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) priced at US$1.01 (Cdn$1.29) per flow-through common share for total gross proceeds of US$12,689,000 (Cdn$16,254,774). The Offering was completed through a syndicate of underwriters led by Cantor Fitzgerald Canada Corporation as sole bookrunner and included H.C. Wainwright & Co., LLC and A.G.P./Alliance Global Partners.